Schedule I - Condensed Financial Information of Registrant - Parent Company Condensed Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net income (loss)	$ (85,231)	$ (86,091)	$ (101,650)	$ (55,433)	$ (73,775)	$ 28,739	$ (16,186)	$ 31,078	$ (328,405)	$ (30,143)	$ 30,586
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash interest									2,750	9,389	9,994
Amortization of deferred financing costs									1,161	785	847
Losses from investments in investees									383	629	480
Equity-based compensation – employees and non-employees									18,509	13,632	8,947
Non-cash revenue from the transfer of intellectual property									0	(3,801)	0
Realized gain on equity securities and disposal of fixed assets									(455)	(33,922)	(10,681)
Change in fair value of derivative instruments and equity securities									153,835	3,967	(101)
Loss on conversion of the 2025 Notes									0	11,111	0
Gain on sale of GeneDx									(18,559)	0	0
Net cash used in operating activities									(95,189)	38,337	39,476
Cash flows from investing activities:
Investments in investees									0	(2,000)	0
Net cash (used in) provided by investing activities									91,038	35,949	(18,327)
Cash flows from financing activities:
Net cash (used in) provided by financing activities									22,971	(10,350)	(35,076)
Net increase (decrease) in cash and cash equivalents									18,481	62,499	(13,241)
Cash and cash equivalents at beginning of period				134,710				72,211	134,710	72,211	85,452
Cash and cash equivalents at end of period	153,191				134,710				153,191	134,710	72,211
SUPPLEMENTAL INFORMATION:
Interest paid									7,420	8,515	10,908
Income taxes paid, net of refunds									8,037	5,969	(903)
Non-cash financing:
Common Stock options and warrants, surrendered in net exercise									1,268	0	0
Issuance of common stock for acquisition of ModeX									221,662	0	0
Fair value of shares included in consideration from GeneDx Holdings									172,000	0	0
Parent Company
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net income (loss)									(328,405)	(30,143)	30,586
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash interest									2,750	9,389	9,994
Amortization of deferred financing costs									1,093	722	787
Losses from investments in investees									383	629	480
(Income) loss from subsidiaries									126,425	(70,313)	(86,429)
Equity-based compensation – employees and non-employees									18,509	13,632	8,947
Non-cash revenue from the transfer of intellectual property									0	(3,801)	0
Realized gain on equity securities and disposal of fixed assets									0	(2,981)	(10,324)
Change in fair value of derivative instruments and equity securities									154,473	4,871	(6)
Loss on conversion of the 2025 Notes									0	11,111	0
Adoption of ASC 326 and other									0	0	(1,311)
Gain on sale of GeneDx									(18,559)	0	0
Changes in other assets and liabilities									(14,993)	10,970	(243)
Net cash used in operating activities									(58,324)	(55,914)	(47,519)
Cash flows from investing activities:
Investments in investees									0	(2,000)	0
Subsidiary financing									23,866	69,608
Subsidiary financing											(23,234)
Proceeds from sale of equity securities									115,423	8,078	15,110
Net cash (used in) provided by investing activities									139,289	75,686	(8,124)
Cash flows from financing activities:
Proceeds from the exercise of Common Stock options and warrants									(774)	1,080	756
Net cash (used in) provided by financing activities									(774)	1,080	756
Net increase (decrease) in cash and cash equivalents									80,191	20,852	(54,887)
Cash and cash equivalents at beginning of period				$ 24,592				$ 3,740	24,592	3,740	58,627
Cash and cash equivalents at end of period	$ 104,783				$ 24,592				104,783	24,592	3,740
SUPPLEMENTAL INFORMATION:
Interest paid									7,420	8,515	10,908
Income taxes paid, net of refunds									8,037	5,969	(903)
Non-cash financing:
Common Stock options and warrants, surrendered in net exercise									1,268	0	0
Issuance of common stock for acquisition of ModeX									221,662	0	0
Fair value of shares included in consideration from GeneDx Holdings									$ 172,000	$ 0	$ 0